HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis
HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis
复制标题
DOI：
10.3109/07357907.2011.584586
复制
发表时间：
2011-06-01
影响因子：
2.4
通讯作者：
Young, Leonie
中科院分区：
文献类型：
--
作者：
Al-azawi, Dhafir;Leong, Sum;Young, Leonie
p53和HER-2在乳腺癌中的共表达一直存在争议。使用免疫组织化学和HercepTest检测这些标志物。HER-2表达与乳腺癌生存率降低相关（p = 0.02）。p53表达与HER-2表达相关（p = 0.029）。p53与HER-2的共表达与预后无关。在单变量和多变量分析中，HER-2阳性和p53阴性表达的组合与不良预后相关（分别为p = .018和p = .027），而HER-2阴性和p53阳性表达的组合与良好预后相关（分别为p = .022和p = .010）。因此，这些标记物的表达应被集体考虑。
p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02). p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.